Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo

NCT07047612 is registered in ClinicalTrials.gov with Beijing InnoCare Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT07047612
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07047612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo
Lead sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Phase
Phase 2/3
Overall status
Recruiting
Start date
May 9, 2025
Completion date
April 30, 2029
Enrollment
603 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

non segmental vitiligo